LabCorp, a Burlington-based medical testing company, is joining forces with Duke University to develop new treatments for various diseases.
The Biomarker Factory joint venture will seek to commercialize new tools that can help improve treatments for heart disease, cancer and other ailments.
By using so-called biomarkers, researchers hope to identify how a patient will respond to a specific therapy, to predict disease progression and more.
"“The Biomarker Factory will contribute greatly to the realization of the promise of individualized medicine and will assist physicians in understanding how to use newly developed biomarkers to improve patient outcomes and reduce healthcare costs,” said LabCorp CEO David King, in a prepared statement.

At this point, the